Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 2888-2896

  Iwako, Hiroshi ^a   Tashiro, Hirotaka ^a   Amano, Hironobu ^a   Tanimoto, Yoshisato ^a   Oshita, Akihiko ^a   Kobayashi, Tsuyoshi ^a   Kuroda, Shintaro ^a   Tazawa, Hirofumi ^a   Nambu, Junko ^a   Mikuriya, Yoshihiro ^a   Abe, Tomoyuki ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III;

ABLATION THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION THERAPY; PREOPERATIVE CARE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; ANTITHROMBIN III; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84867404916     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2338-y     Document Type: Article

References (35)

1. Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:1-14.
2. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GAM, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-35.
3. Rosenberg RD. Biochemistry of heparin antithrombin interaction, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 1989;87:2S-9S.
4. Larsson H, Sjöblom T, Dixelius J, Östman A, Ylinenjärvi K, Björk I, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000;60:6723-9.
5. Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001;61:7298-304.
6. Buller HR, Boon TA, Henny CP, Dabhoiwala NF, ten Cate JW. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol. 1982;128:72-4.
7. Honegger H, Anderson N, Hewitt LA, Tullis JL. Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites. Thromb Haemost. 1981;46:500-3.
8. Mulder AB, Zwaveling JH, Smid WM, Maring JK, van Ginkel RJ, Girbes AR, et al. Augmented procoagulant activity in cancer patients treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost. 1996;76:897-901.
9. Itamoto T, Katayama K, Nakahara H, Tashiro H, Asahara T. Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. Br J Surg. 2003;90:23-8.
10. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9:298-304.
11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
12. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346-50.
13. Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson's pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery. 2001;130:443-8.
14. Sakuragawa N, Hasegawa H, Maki M, Nakagawa, Nakashima M. Clinical evaluation of low molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC)-a multicenter cooperative double-blind trial in comparison with heparin. Thromb Res. 1993;72:475-500.
15. Aoki N, Yoshida M, Yamanaka T. Treatment of DIC with antithrombin III concentrate (in Japanese). Igakunoayumi. 1979;109:970-4 (in Japanese)
16. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-96.
17. Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol. 2008;103:262-6.
18. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986;91:41-8.
19. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-63.
20. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-81.
21. Kurata M, Okajima K, Kawamoto T, Uchiba M, Ohkochi N. Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells. World J Gastroenterol. 2006;12:60-5.
22. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL. Macrophage migration inhibitory factor anti-thrombin III complex formation as a mechanism of inactivation. Cancer Lett. 2010;290:49-57.
23. Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin upregulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008;68:4666-73.
24. Hu L, Ibrahim S, Liu C, Skaar J, Pagano M, Karpatkin S. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the upregulation of skp2 and mir-222. Cancer Res. 2009;69:3374-81.
25. Hu L, Roth JM, Brooks P, Ibrahim S, Karpatkin S. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res. 2008;68:4296-302.
26. Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol. 2007;211:699-707.
27. Rullier A, Senant N, Kisiel W, Bioulac-Sage P, Balabaud C, Bail BL, et al. Expression of protease-activated receptors and tissue factor in human liver. Virchows Arch. 2006;448:46-51.
28. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-71.
29. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Human Pathol. 2008;39:1777-83.
30. Mi Z, Oliver T, Guo H, Kuo PC. Thrombin-cleaved COOH (-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007;67:4088-97.
31. Xue YH, Zhang QZ, Sun J, Dai C, Zhou HJ, Ren N, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010;52:2012-22.
32. Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, Kajiyama K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80-5.
33. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703-10.
34. Poon RTP, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma; long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216-22.
35. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguchi M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381-8.